Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Solifenacin and Mirabegron on Digoxin PK
NCT02127034Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of solifenacin and mirabegron in overactive bladder (OAB) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration at Day 10 and Area Under the Curve over dosing interval at Day 10. Started Mar 2014; status: completed.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02127034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127034.